期刊文献+

黄嘌呤类DPP-Ⅳ抑制剂的化学合成和生物活性研究 被引量:1

Synthesis and biological activity of substituted xanthines as DPP-Ⅳ inhibitors
原文传递
导出
摘要 为了考察降血糖药物利拉利汀(linagliptin,LNP)的黄嘌呤结构母核上N-1、N-7和C-8取代基对DPP-Ⅳ酶抑制活性的贡献,并且希望找到活性更强的新DPP-Ⅳ抑制剂,本研究以3-甲基-8-溴黄嘌呤为原料,通过引入不同取代基,设计合成一系列LNP的类似物,并测定这些化合物对DPP-Ⅳ酶的抑制率。活性测定结果显示,这类化合物在50 nmol·L^(-1)浓度下大多具有明显的DPP-Ⅳ酶抑制活性,其中1a、1d和1f对DPP-Ⅳ酶的抑制率大于50%。本研究初步探索了黄嘌呤类化合物对DPP-Ⅳ酶抑制活性的构效关系,为以后的研究提供了新的思路和借鉴。 In order to find more potential DPP-Ⅳ inhibitor, a series of xanthine-scaffold analogs of linagliptin, an approved antidiabetes drug, were designed and synthesized for SAR study. All compounds with a concentration of 50 nmol·L^(-1) showed the inhibitory activity against DPP-Ⅳ enzyme in vitro, and the inhibition rate of compounds 1a, 1d and 1f was over 50%. Virtual docking was also performed to facilitate the SAR analysis of these substituted xanthines.
出处 《药学学报》 CAS CSCD 北大核心 2016年第6期947-953,共7页 Acta Pharmaceutica Sinica
基金 北京市自然科学基金资助项目(7132166)
关键词 二肽基肽酶-4抑制剂 利拉利汀 合成 构效关系 dipeptidyl peptidase Ⅳ inhibitor linagliptin synthesis SAR
  • 相关文献

参考文献14

  • 1Hiramatsu H, Kyono K, Higashiyama Y, et al. The structure and function of human dipeptidyl peptidase IV, possessing a unique eight-bladed-propeller fold [J]. Biochem Biophys Res Commun, 2003, 302: 849-854.
  • 2Rasmussen HB, Branner S, Wiberg FC, et al. Crystal structure of human dipeptidylpeptidase 1V/CD26 in complex with a substrate analog [J]. Nat Struct Biol, 2003, 10:19 -25.
  • 3Engel M, Hoffmann T, Wagner L, et al. The crystal structure of dipeptidyl peptidase Ⅳ (CD26) reveals its functional regulation and enzymatic mechanism [J]. Proc Natl Acad Sci USA, 2003, 100: 5063-5068.
  • 4Oefner C, D'Arcy A, Sweeney AM, et al. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[({2-[(5-iodopyridin-2-yl)amino]-ethyl}amino)- acetyl]-2-cyano-(S)-pyrrolidine [J]. Acta Cryst, 2003, D59: 1206-1212.
  • 5Peters JU, Weber S, Kritter S, et al. Aminomethylpyrimidines as novel DPP-Ⅳ inhibitors: a 105-fold activity increase by optimization of aromatic substituents [J]. Bioorg Med Chem Lett, 2004, 14:1491-1493.
  • 6Campbell JE, Drucker DJ. Pharmacology, physiology, andmechanisms of incretin hormone action [J]. Cell Metab, 2013, 17: 819-837.
  • 7Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 [J]. Proc Natl Acad Sci USA, 2000, 97: 6874-6879.
  • 8Kim D, Wang L, Beconi M, et al. (2R)-4-Oxo-4-β- (trifluoromethyl)-5,6-dihydro[ 1,2,4]triazolo[4,3 -a]pyrazin-7(8 H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase 1V inhibitor for the treatment of type 2 diabetes [J]. J Med Chem, 2005, 48:141-151.
  • 9ViUhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-Hydroxy- 1-admantyl)amino]acetyl]-2-cyano-(S) pyrrolidine: a potent, selective and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemia properties [J]. J Med Chem, 2003, 46: 2774-2789.
  • 10Augeri D J, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase Ⅳ inhibitor for the treatment of type 2 diabetes [J]. J Meal Chem, 2005, 48: 5025-5037.

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部